Stockscreener 앱 받기
7.94
3.41%
-0.28
시간 외 거래:
7.90
-0.04
-0.50%
전일 마감가:
$8.22
열려 있는:
$8.01
하루 거래량:
52,624
Relative Volume:
0.61
시가총액:
$293.50M
수익:
$4.71M
순이익/손실:
$-46.77M
주가수익비율:
-4.7284
EPS:
-1.6792
순현금흐름:
$-60.34M
1주 성능:
+1.28%
1개월 성능:
+2.98%
6개월 성능:
-26.69%
1년 성능:
-12.75%
1일 변동 폭
$7.8248
$8.015
1주일 범위
$7.77
$8.37
52주 변동 폭
$5.55
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
NYXH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
7.94 | 293.50M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
516.12 | 185.10B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
175.33 | 50.76B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.16 | 43.19B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
261.07 | 37.26B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
210.08 | 16.13B | 2.90B | 467.20M | 306.90M | 6.37 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-31 | 개시 | H.C. Wainwright | Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Neutral |
| 2022-04-21 | 개시 | Oppenheimer | Outperform |
| 2022-04-06 | 개시 | Wolfe Research | Peer Perform |
| 2021-12-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-07-28 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Nyxoah Sa 주식(NYXH)의 최신 뉴스
What analysts say about Nyxoah SA stockHigh-yield trading alerts - Autocar Professional
What drives Nyxoah SA stock priceBreakout portfolio performance - jammulinksnews.com
Trend Tracker for (NYXH) - news.stocktradersdaily.com
Is Nyxoah SA a good long term investmentBreakthrough profits - Autocar Professional
Nyxoah SA Stock Analysis and ForecastFree Stock Market Real-Time Monitoring - jammulinksnews.com
Nyxoah’s Innovative Approach to Sleep Apnea: A Clinical Study Update - TipRanks
Is Nyxoah SA stock a growth or value playControlled Risk High Reward Plan - Newser
What makes Nyxoah SA stock price move sharplyShort Squeeze Radar - Newser
Why Nyxoah SA stock attracts strong analyst attentionFree Access to Investment Community - Newser
How Nyxoah SA stock performs during market volatilitySmart High Yield Swing Trades - Newser
Nyxoah SA Announces New Share Issuance to Strengthen Financial Structure - TipRanks
(NYXH) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025 - yahoo.co
Major Governance Shift: Nyxoah Grants Long-term Shareholders New Board Nomination Rights - Stock Titan
Cantor Fitzgerald Forecasts Nyxoah FY2026 Earnings - Defense World
Ameriprise Financial Inc. Takes $135,000 Position in Nyxoah S.A. (NASDAQ:NYXH) - Defense World
When the Price of (NYXH) Talks, People Listen - news.stocktradersdaily.com
Top Premarket Decliners - marketscreener.com
Millennium Management LLC Trims Stock Holdings in Nyxoah S.A. (NASDAQ:NYXH) - Defense World
Nyxoah Announces Change in Shareholder Voting Rights - TipRanks
Vestal Point Capital Cuts Nyxoah Holdings by 40%: Major Ownership Shift Revealed - Stock Titan
Nyxoah to Present at the Jefferies Global Healthcare Conference - The Manila Times
Nyxoah CEO Showcases Revolutionary Sleep Apnea Treatment at Major Jefferies Healthcare Conference - Stock Titan
Nyxoah SA Updates Share Capital and Voting Rights - TipRanks
Information on the total number of voting rights and shares - Yahoo
Head-To-Head Survey: Inspire Medical Systems (NYSE:INSP) versus Nyxoah (NASDAQ:NYXH) - Defense World
Cantor maintains Nyxoah stock Overweight with $14 target By Investing.com - Investing.com Nigeria
Nyxoah Announces CE Mark Approval For Genio® 2.1 - Barchart.com
Cantor maintains Nyxoah stock Overweight with $14 target - Investing.com
Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates - MSN
Trading (NYXH) With Integrated Risk Controls - news.stocktradersdaily.com
Nyxoah Sa’s Earnings Call: Progress Amid Challenges - TipRanks
Nyxoah outlines U.S. Genio launch plan with 50-member team as FDA approval expected Q2 2025 - MSN
Nyxoah S.A. (NASDAQ:NYXH) Q1 2025 Earnings Call Transcript - Insider Monkey
Nyxoah Reports Q1 2025 Financial Results and FDA Progress - TipRanks
Nyxoah Q1 2025 Earnings Call Transcript - MarketBeat
Nyxoah Nears FDA Approval for Genio® System Amid Q1 2025 Results - TipRanks
Nyxoah (NYXH) Nears FDA Approval for Genio System in the U.S. | - GuruFocus
Nyxoah Sa (NYXH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.28%
자본화:
|
볼륨(24시간):